Search

Displaying results 401 - 410 of 10000 in total
  1. Target

    Cytochrome c1, heme protein, mitochondrial

    go.drugbank.com/bio_entities/BE0003854
    TargetHumans

    The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … Cytochrome c1 is a catalytic core subunit containing a c-type heme. It transfers electrons from the [2Fe-2S] iron-sulfur cluster of the Rieske protein to cytochrome c

    Synonyms: Complex III subunit 4, Complex III subunit IV
  2. Target

    Cytochrome b

    go.drugbank.com/bio_entities/BE0000938
    TargetHumans

    Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex) that is part of the mitochondrial respiratory chain. … The b-c1 complex mediates electron transfer from ubiquinol to cytochrome c. Contributes to the generation of a proton gradient across the mitochondrial membrane that is then used for ATP synthesis

    Synonyms: Complex III subunit 3, Complex III subunit III
  3. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology … BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.

    Products: 1 Ranivisio, LUCENTIS® 10 MG /ML SOLUCION INYECTABLE
  4. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [L39267] Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. … Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: LIKMUN-E, P-HYSPLAN
  5. Target

    Pseudoazurin

    go.drugbank.com/bio_entities/BE0001952
    TargetAlcaligenes faecalis

    This soluble electron transfer copper protein is required for the inactivation of copper-containing nitrite reductase in the presence of oxygen.

    Synonyms: Blue copper proteinFunction: copper ion binding
  6. Drug

    Remdesivir

    go.drugbank.com/drugs/DB14761
    ApprovedInvestigational

    [L18438] Remdesivir was also approved by the European Commission on July 3, 2020. … Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues.

    Categories: MATE 1 Inhibitors, P-glycoprotein substratesProducts: VEKLURY® LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIAL, VEKLURY 100 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADET
  7. Target

    Tumor susceptibility gene 101 protein

    go.drugbank.com/bio_entities/BE0019070
    TargetHumans

    Component of the ESCRT-I complex, a regulator of vesicular trafficking process. … Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in cell growth and differentiation.

    Synonyms: ESCRT-I complex subunit TSG101
  8. Drug

    Infliximab

    go.drugbank.com/drugs/DB00065
    ApprovedInvestigational

    Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469]. … Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases [A31469].

    Synonyms: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMERCategories: Complex Mixtures
  9. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a … Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: MEKINIST®2 MG TABLETAS RECUBIERTAS, MEKINIST 2 MG FILM KAPLI TABLET ,7 TABLET
  10. Drug

    DL-alpha tocopheryl acetate

    go.drugbank.com/drugs/DB14477
    Approved

    Mixtures: Vena-Bal DHA, Stress B Complex With C,e, Zinc and CopperCategories: Vitamin E